MetaVia doses first patient in 48 mg MAD cohort of Phase 1 obesity trial; Q4 top-line data expected

MetaVia Inc.

First patient dosed in 48 mg multiple ascending dose cohort of DA-1726 (GLP1R/GCGR dual agonist) for obesity.
Prior 32 mg data: mean weight loss 4.3%, max 6.3% at Day 26 (p=0.0005); 83% early satiety; average waist reduction 1.6 inches by Day 33.
Fasting glucose reduced up to 18 mg/dL without hypoglycemia; no QTcF prolongation; mild GI side effects, suggesting favorable tolerability.
CEO stated DA-1726 has best-in-class potential with no titration needed; top-line results from 48 mg cohort expected Q4 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.